Table 1 Participant demographics

Sample size

23

10

43

N/A

Age, median ± SD

84.0 ± 12.9

68.0 ± 6.9

47.0 ± 10.3

<0.0001^a

Sex, % female (n)

60.9 (14)

70.0 (7)

60.5 (26)

0.8922^b

First dose vaccine type

11 BNT162b2

12 mRNA-1273

8 BNT162b2

2 mRNA-1273

43 BNT162b2

<0.0001^b

Days between dose 1 and dose 2 (median ± SD)

27.0 ± 3.4

76.5 ± 18.5

28.0 ± 28.7

<0.0001^a

Second dose vaccine type

11 BNT162b2

12 mRNA-1273

8 BNT162b2

2 mRNA-1273

41 BNT162b2

2 mRNA-1273

<0.0001^b

Days between dose 2 and dose 3 (median ± SD)

218.0 ± 9.2

138.0 ± 23.0

254.5 ± 45.1

<0.0001^a

Third dose vaccine type^c

11 BNT162b2

12 mRNA-1273

8 BNT162b2

2 mRNA-1273

15 BNT162b2

13 mRNA-1273

2 unknown

0.2609^b

Days between dose 3 and dose 4 (median ± SD)

133.0 ± 9.0

104.0 ± 38.8

245.0 ± 15.2

<0.0001^a

Fourth dose vaccine type^c

1 BNT162b2

17 mRNA-1273

3 BNT162b2

5 mRNA-1273

4 BNT162b2

3 mRNA-1273

0.0091^b